Physician profile
Edward Clark
NPI 1730294232
$5,035.51
in general payments reported to CMS, 2019-2025
32 companies · $2,833 in 2025
The $2,833 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $189 · 2021: $278 · 2022: $390 · 2023: $241 · 2024: $963 · 2025: $2,833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $837.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $837.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $3,218.01 | 2024-2025 | Bovine Collagen |
| Abbvie INC. | $460.13 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $206.17 | 2022-2025 | |
| Novo Nordisk INC | $177.73 | 2021-2025 | Wegovy, Saxenda |
| Corcept Therapeutics | $130.22 | 2025 | Korlym |
| Lsi Solutions INC | $111.38 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.52 | 2025 | Trintellix |
| Exeltis, USA INC. | $67.64 | 2019-2022 | |
| Lilly USA, LLC | $55.68 | 2024-2025 | Zepbound, Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.08 | 2025 | Caplyta |
| Therapeuticsmd, INC. | $48.24 | 2020-2021 | |
| Pfizer INC. | $46.98 | 2023-2024 | |
| Dexcom, INC. | $44.06 | 2025 | Dexcom G6 Transmitter |
| Channel Medsystems, INC. | $32.06 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.89 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $27.32 | 2019-2024 | |
| Allergan, INC. | $23.28 | 2019-2020 | |
| Shield Therapeutics INC | $20.69 | 2024 | |
| Exact Sciences Corporation | $19.77 | 2025 | Cologuard Collection Kit |
| Organon LLC | $18.71 | 2024 | |
| Rhythm Pharmaceuticals, INC. | $18.34 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.78 | 2019 | |
| Myovant Sciences INC. | $16.91 | 2022 | |
| Millicent US INC | $16.60 | 2023 | Intrarosa |
| Conmed Corporation | $16.32 | 2025 | Airseal |
| Merck Sharp & Dohme LLC | $15.70 | 2021 | |
| Amag Pharmaceuticals, INC. | $13.26 | 2019 | |
| Baxter Healthcare | $13.14 | 2021 | |
| Astellas Pharma US INC | $13.13 | 2023 | Veozah |
| Dysis Medical, INC. | $13.12 | 2020 | |
| Meditrina | $13.01 | 2023 | |
| Boston Scientific Corporation | $6.64 | 2025 | Bulkamid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.